"Pharmacokinetic Study of Nicotinamide Riboside"

Completed · Phase 1

Conditions studied: Metabolic Disturbance

In brief

Nicotinamide riboside (NR) has been available over the counter as a nutraceutical (Niagen®, ChromaDex, Inc.) since the summer of 2013. However, classical pharmacokinetic (PK) data for NR have not been reported in humans. This study will use a recently-developed, whole blood assay for NR to assess the pharmacokinetics of NR at a maximum dose of 1000 mg twice daily, and will collect history, physical examination and laboratory data to determine the safety and tolerability of NR in eight, healthy volunteers. In addition, whole blood nicotinamide adenine dinucleotide (NAD) levels will be measured at each time point, to determine whether this NR dose significantly raises whole blood NAD levels.

Key facts

Study ID

NCT02689882

Run by

University of Washington

People needed

8

Starts

2015-11-01

Expected to finish

2016-02-01

Last updated by the study team

2018-02-08

Who can join

Age: 21 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy, adult (age 21-50 years), male or female
• Willing and able to provide informed consent

You may not qualify if…

• Current smoking
• Receiving concurrent medications or supplements
• History of liver, renal, cardiovascular, endocrine, or neurological disease
• Known allergy to niacin or nicotinamide ribosome
• Unwilling to refrain from drinking alcohol during the duration of the study

Where it is running

• University of Washington — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.